ImageneBio, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $800,000 | $3.5M | $9.2M | $15.6M | $31.0M |
| Operating income | -$48.5M | -$37.0M | -$75.4M | -$70.9M | -$34.1M |
| Operating expenses | $49.3M | $40.5M | $84.6M | $86.5M | $65.1M |
| Cash from operations | -$47.8M | -$21.3M | -$79.7M | -$74.1M | -$60.3M |
| Capital expenditure | — | — | $414,000 | $1.4M | $1.8M |
| Free cash flow | — | — | -$80.2M | -$75.5M | -$62.0M |
| Share repurchases | — | — | $663,000 | — | — |
| Impairments | — | — | $0 | $0 | $0 |
| Total assets | $153.0M | $15.9M | $192.1M | $172.3M | $247.9M |
| Total liabilities | $19.8M | $17.4M | $22.3M | $25.3M | $40.0M |
Shares outstanding 11.3M · Free float 81.2%
Annual filing data through FY ended December 31, 2025; float as of June 27, 2026.